Duration of adjuvant chemotherapy for breast cancer: a joint analysis of two randomised trials investigating three versus six courses of CMF.
about
A small sample study of the STEPP approach to assessing treatment-covariate interactions in survival data.Differential efficacy of three cycles of CMF followed by tamoxifen in patients with ER-positive and ER-negative tumors: long-term follow up on IBCSG Trial IX.Metabolism and transport of oxazaphosphorines and the clinical implications.Moderate neutropenia with adjuvant CMF confers improved survival in early breast cancer.The association between the duration of fluoropyrimidine-based adjuvant chemotherapy and survival in stage II or III gastric cancer.Dose dense cyclophosphamide, methotrexate, fluorouracil is feasible at 14-day intervals: a pilot study of every-14-day dosing as adjuvant therapy for breast cancer.The effect of endocrine responsiveness on high-risk breast cancer treated with dose-intensive chemotherapy: results of International Breast Cancer Study Group Trial 15-95 after prolonged follow-up.Can some patients avoid adjuvant chemotherapy for early-stage breast cancer?CMF revisited in the 21st century.Subpopulation Treatment Effect Pattern Plot (STEPP) analysis for continuous, binary, and count outcomes.Symptom incidence, distress, cancer-related distress, and adherence to chemotherapy among African American women with breast cancer.Timing of Radiation Therapy and Chemotherapy After Breast-Conserving Surgery for Node-Positive Breast Cancer: Long-Term Results From International Breast Cancer Study Group Trials VI and VII.Prognosis and adjuvant treatment effects in selected breast cancer subtypes of very young women (<35 years) with operable breast cancer.Outcome of special types of luminal breast cancer.Efficacy of adjuvant chemotherapy with carboplatin for early triple negative breast cancer: a single center experience.Extended Adjuvant Chemotherapy in Triple-Negative Breast Cancer.
P2860
Q33402985-53154595-1849-4C89-903E-77834110B722Q35450768-8F5A904D-9B02-4309-B569-A58FBE6AE775Q36360811-03F5807C-0BAA-4795-90C1-7552288A5A76Q36671677-C989ED2D-1ED6-4C7F-A9D2-DF06277CD558Q36759903-419B2353-8606-41EE-B0D8-5B0925CEEA9CQ36866229-1DDECF92-4F5B-419D-83B0-4950AE14BAC5Q37289219-53B8A4FA-D98A-46E3-B2FC-CDAA3E14E624Q37848654-0CCD1AF2-009B-488C-B8F0-5E70D0D7A8B4Q37895805-4435C0F7-F041-4C60-88FD-BC35BBE98B09Q38380910-804F66CB-BA2C-4F1D-84E5-77CB80278BB8Q40335346-2FEB4CBA-F1BE-4422-9F6D-AAB29C1CE504Q40593447-B37723D1-4265-42CC-9546-CB40F1A3A550Q43120755-55C0752B-CB59-47D9-9037-EB2FA98A1B12Q43599744-A21C6852-5166-4FFB-AAF2-958AFB535F1EQ46251266-37202330-26D0-4918-B9C8-13BD4245EF92Q55383509-D2FE7E52-9373-432B-8384-92FD617E2FBC
P2860
Duration of adjuvant chemotherapy for breast cancer: a joint analysis of two randomised trials investigating three versus six courses of CMF.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
2002年论文
@zh
2002年论文
@zh-cn
name
Duration of adjuvant chemother ...... ree versus six courses of CMF.
@ast
Duration of adjuvant chemother ...... ree versus six courses of CMF.
@en
type
label
Duration of adjuvant chemother ...... ree versus six courses of CMF.
@ast
Duration of adjuvant chemother ...... ree versus six courses of CMF.
@en
prefLabel
Duration of adjuvant chemother ...... ree versus six courses of CMF.
@ast
Duration of adjuvant chemother ...... ree versus six courses of CMF.
@en
P2093
P2860
P356
P1476
Duration of adjuvant chemother ...... hree versus six courses of CMF
@en
P2093
A Goldhirsch
A S Coates
B Thürlimann
C-M Rudenstam
D Crivellari
German Breast Cancer Study Group
H J Litman
P2860
P2888
P304
P356
10.1038/SJ.BJC.6600334
P407
P577
2002-06-01T00:00:00Z